FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 545 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR The Power of Fruits and Vegetables December 18, 2020 A Nurse’s Love For Oncology Patients May 20, 2021 Brothers Break Down After Seeing Their Parents For First Time In... October 31, 2021 What to Say to Someone With Cancer: A Patient Perspective July 14, 2022 Load more HOT NEWS Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... Sing Anyway The Healing Power of Being Outdoors for People With Cancer FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour
